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Abstract
Background: To date, there is no standard treatment for unresectable malignant peritoneal
mesothelioma; either best supportive care or systemic chemotherapy with palliative intent are
accepted options.
Case presentation: Here, we report the case of a 79-year old patient with malignant peritoneal
mesothelioma who was treated with pemetrexed single-agent and obtained an impressive long-
lasting response.
Conclusion:  Single-agent pemetrexed is a treatment option for malignant peritoneal
mesothelioma in selected elderly patients or in patients with unpaired performance status.
Background
Malignant peritoneal mesothelioma (MPM) accounts for
10–30% of all malignant mesothelioma cases [1].
Although a direct causal relationship between pleural
mesothelioma and occupational asbestos exposure is
strong [2], only 33% of patients with MPM report a his-
tory of asbestos exposure [3]. Most of the patients present
with abdominal distension and/or pain, and occasionally
bowel obstruction; other signs at presentation include
ascites, tenderness, and palpable masses [2]. Findings at
computed tomography (CT) scan may appear similar to
other metastatic tumours, with nodules, plaques, thicken-
ing, masses involving the parietal and visceral perito-
neum, and lymphadenopathy. A definite diagnosis of
MPM can be difficult and requires histological examina-
tion with appropriate immunohistochemical analysis on
adequate biopsy samples. Malignant mesothelioma is
characterized by the presence of staining for calretinin,
cytokeratin 5/6, and absence of staining for carcinoembry-
onic antigen and MOC-31 (or B72.3, Ber-EP4, or BG-8)
[4].
Prognosis of MPM is dismal and there is no standard treat-
ment approach: although multimodality treatment
including intraperitoneal chemotherapy and cytoreduc-
tive surgery may result in prolonged survival in selected
patients [5], either best supportive care or systemic chem-
otherapy with palliative intent are accepted approaches.
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Here we report a case of an elderly patient with unresecta-
ble MPM treated with single-agent pemetrexed.
Case presentation
In April 2004, a 79-year-old man presented with a 4
month history of subcutaneous abdominal nodules and
bilateral inguinal lymphadenopathy; no other signs or
symptoms were present.
The patient was retired after various occupations; he had
also worked for 7 years at the local port and for 3 years in
a motor factory, but he had no memory of direct exposure
to asbestos. He had no smoking history. Medical history
included partial gastric resection due to gastric and duode-
nal ulcers with concomitant cholecystectomy for chole-
lithiasis at 44, surgical removal of a renal stone at 74,
diagnosis of benign prostatic hypertrophy at 76.
A CT of the chest, abdomen and pelvis showed the pres-
ence of a large mass occupying the epigastrium and the
left upper region of the abdomen (longest diameter: 9
cm), and multiple diffuse abdominal nodules along the
peritoneal surface and below the anterior abdominal wall
(longest diameter: 5 cm); imaging confirmed the presence
of bilateral inguinal lymphadenopathy. A small amount
of ascites was present; liver, spleen and kidneys were
spared. Chest CT was negative, with no evidence of pleural
or pulmonary parenchymal abnormalities. An excisional
biopsy of the left inguinal lymphadenopathy was per-
formed. Histological analysis showed malignant neo-
plasm with a micropapillary, microcystic, and solid
growth pattern infiltrating the adjacent soft tissues.
Immunohistochemical analysis revealed positive staining
of tumour cells for cytokeratins 5 and 7, vimentin, epithe-
lial membrane antigen (EMA), epithelial specific antigen
(ESA), calretinin; no reactivity was observed for carci-
noembryonic antigen or Tag/B72.3. Histological and
immunohistochemical findings were consistent with a
well differentiated biphasic malignancy of mesothelial
origin.
In July 2004 the patient was referred to our Department
for management. At admission, he reported progressive
clinical deterioration (Karnofsky Performance Status 80),
fatigue, unintentional weight loss of 6 kg and persistent
fever over the last few weeks. His medications were terazo-
sine and finasteride. Physical examination showed a sub-
cutaneous epi-mesogastric mass (9 × 6 cm) and bilateral
inguinal lymphadenopathy. Complete blood count
showed haemoglobin 11.6 g/dL, platelet count 559,000
per cubic millimeter, and white cell count 8,400 per cubic
millimeter, with a normal differential count; renal func-
tion and liver function tests were normal.
In consideration of patient's age, and type and stage of dis-
ease, palliative chemotherapy with single-agent peme-
trexed at 500 mg/m2 i.v. every 3 weeks was proposed [6].
Pemetrexed was provided by Eli Lilly (Indianapolis, IN)
within an Expanded Access Programme. Before chemo-
therapy start, a written informed consent was obtained
and a repeat CT was performed, showing a size increase of
all lesions (longest diameter of the mass in the abdominal
left upper region: 12 cm) (Fig. 1a). Treatment started in
early August 2004. During the treatment, the patient
received vitamin B12 and folic acid supplementation, and
steroid prophylaxis [6]. After the first 2 cycles, a clinical
improvement was observed with reduction of frequency
and intensity of febrile episodes. Partial response was doc-
umented by physical examination (decrease in size of the
subcutaneous abdominal mass and bilateral inguinal
nodes) and by CT (decrease in size of all known lesions
and no new lesions). Treatment was well tolerated with
only grade 2 neutropenia, and grade 2 nausea and ano-
rexia. Therefore, pemetrexed was continued for 3 cycles
and further tumour shrinkage was documented at physi-
cal examination and imaging. Toxicity persisted accepta-
ble with only grade 2 nausea and fatigue; fever
disappeared after the third cycle. Three further cycles of
pemetrexed were administered without increase in toxic-
ity except for mild fever lasting few days after drug admin-
istration. After a total of 8 cycles, the epi-mesogastric mass
and the inguinal bilateral lymphadenopathy were no
more detectable at physical examination, whereas abdom-
inal CT in April 2005 showed a minimal residue of disease
(Fig. 1b). His Karnofsky Performance Status was 80 and
his weight was increased of approximately 10% since
treatment start. At that point, after multidisciplinary eval-
uation and discussion with the patient about therapeutic
options, we decided to stop the treatment.
In August 2005, a follow-up CT revealed the reappearance
of nodular peritoneal lesions. Due to the significant ben-
efit observed and the duration of response (11 months)
the patient was retreated with pemetrexed for 4 cycles
from August to November 2005, resulting in disease stabi-
lization. At the time of his last appointment at our Depart-
ment in February 2006, a CT scan confirmed stable
disease.
Discussion
The efficacy of systemic chemotherapy as well as chemo-
therapy regimens to be used in patients with MPM are
mainly extrapolated from studies in patients with malig-
nant pleural mesothelioma. In a randomized phase III
trial in malignant pleural mesothelioma, pemetrexed, a
novel multitargeted antifolate, showed significantly
longer survival in combination with cisplatin compared
to cisplatin alone (median survival 12.1 vs. 9.3 months; p
< 0.02) [7].BMC Cancer 2006, 6:289 http://www.biomedcentral.com/1471-2407/6/289
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A subset analysis of data from patients with MPM in an
expanded access program showed a favourable safety pro-
file and encouraging activity for pemetrexed alone or in
combination with cisplatin, both in the first- and in the
second-line setting [8]. Disease control rate (complete
response + partial response + stable disease) was 71%;
overall response rate was 25% and 23% in chemonaive (n
= 28) and previously treated (n = 43) patients, respec-
tively. The most common adverse events (i.e. dehydra-
tion, nausea, vomiting) were clinically manageable. In
that series, only 3 chemotherapy-naive patients who
received pemetrexed single agent were included: no
response was observed (2 stable disease, 1 progressive dis-
ease). Here, we report durable disease control in an eld-
erly chemo-naive patient with MPM, obtained with
pemetrexed single agent, without significant toxicity.
Due to the favourable toxicity profile and activity in MPM,
pemetrexed single-agent may be a treatment option for
selected elderly patients and patients unfit for a platinum
based chemotherapy. A prospective clinical trial should be
conducted to confirm this indication. However, MPM is a
rare tumour; large trials evaluating new treatment
approaches in this setting, especially in selected patients
(i.e. elderly or poor performance status patients), are in
general not feasible.
Conclusion
Although the use of pemetrexed in malignant mesotheli-
oma is mostly supported in combination with platinum,
our report suggests that single-agent pemetrexed may be
considered for selected elderly or unfit patients with
MPM.
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